Across TCGA pan-cancer cohorts, MIR618 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR618’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR618 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR618 is over-expressed in tumor.
BRCA and KICH are the cancer types where MIR618 tumor–normal differential expression is most reproducible.